文献速递白血病

表观遗传学治疗清除核心结合因子急性髓系白血病微小残留病

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2017-06-09

该研究纳入23例核心结合因子急性髓系白血病(CBF-AML)患者,在FLAG方案联合低剂量吉妥珠单抗或伊达比星诱导/巩固后接受去甲基化药物(HMA)维持治疗,评估实时定量RT-PCR监测的微小残留病(MRD)动态。结果显示,HMA启动时RT-PCR可检测的17例中,5例疾病进展且RT-PCR值在1-2周期HMA内显著升高,12例未失败者中11例在HMA首或第二周期后RT-PCR下降;作者认为诱导/巩固结束时RT-PCR低水平(0.01-0.05)者从HMA维持中获益最大。

要点

  • CBF-AML诱导/巩固后HMA维持可清除MRD,低水平RT-PCR(0.01-0.05)者获益最大。
  • HMA启动时RT-PCR可检测的17例中,5例进展且1-2周期内RT-PCR值显著升高。
  • 12例未失败HMA者中11例在首或第二周期后RT-PCR下降。

核心结论

  • 作者认为,诱导/巩固化疗结束时RT-PCR低水平(0.01-0.05)的CBF-AML患者从HMA维持治疗中获益最大,尤其是那些在HMA治疗前两个周期内RT-PCR下降的患者。

研究设计与样本

  • 研究纳入23例CBF-AML患者(中位年龄53岁),在FLAG方案联合低剂量吉妥珠单抗或伊达比星诱导/巩固后接受HMA(包括地西他滨和阿扎胞苷)维持治疗,并回顾性分析实时定量RT-PCR趋势(NCT00801489)。

主要发现

  • 23例可评估患者中,17例在HMA启动时RT-PCR可检测。
  • 5例疾病进展,且RT-PCR值在1-2周期HMA治疗内显著升高。
  • 12例未失败HMA,HMA启动时RT-PCR中位值为0.06(范围0.01-0.91);其中11例在HMA第一或第二周期后RT-PCR下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recurrent translocations, t(8;21) or inv(16), in core binding factor acute myeloid leukemia (CBF-AML) are amenable to monitoring for minimal residual disease (MRD) with reverse transcriptase polymerase chain reaction (RTPCR). Despite a favorable prognosis, disease relapse remains the single cause of treatment failure in CBF-AML. Fusion products of these translocations recruit epigenetic silencing complexes resulting in hematopoietic maturation arrest. We hypothesized that maintenance therapy with hypomethylating agents (HMA), including decitabine (DAC) and azacitidine (AZA) after induction/consolidation, can be used for MRD elimination to ultimately prolong relapse free survival. Real-time quantitative (RTPCR) trends were reviewed in 23 patients (median age 53 years) with CBF-AML that received HMA therapy following induction/consolidation with fludarabine, cytarabine, and G-CSF (FLAG) with low dose gemtuzumab or idarubicin (NCT00801489). Of the 23 patients evaluated, 17 had a detectable RTPCR at HMA initiation. Five patients had progressive disease and a notable increase in RTPCR values over 1-2 cycles of HMA therapy. Twelve patients did not fail HMA and had a median RTPCR at HMA initiation of 0.06 (range, 0.01-0.91). Unlike the HMA failure subset, 11 of these patients had a reduction in RTPCR after the first or second cycle of HMA. Our data suggests that CBF-AML patients with low levels of RTPCR (between 0.01 and 0.05) at the conclusion of induction/consolidation chemotherapy benefit most from maintenance HMA, particularly those that have a reduction in the RTPCR within the first two cycles of HMA therapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ragon BK, Daver N, Garcia-Manero G, et al. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017. PMID: 28494506. doi:10.1002/ajh.24782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。